biotech
biotech Articles
Biogen shares rocketed up on Wednesday after briefing documents from the FDA provided evidence of the effectiveness of the firm’s Alzheimer’s disease treatment.
Published:
Aurinia Pharma shares slid on Tuesday after the company reported results from its midstage study for the treatment of dry eye syndrome.
Published:
DBV Technologies is making a comeback after making headway for its peanut allergy treatment in Europe.
Published:
Equillium shares jumped on Friday after the company announced a key update from the FDA regarding its late-stage COVID-19 trial.
Published:
When Moderna reported its most recent quarterly results before the markets opened on Thursday, the earnings (or loss in this case) were not the most important feature of the report.
Published:
The novel coronavirus has wiped out trillions of dollars in global output with more than 1 million deaths worldwide in 2020. With cases rising rapidly in the United States and in Europe, more...
Published:
Amgen and Gilead released their most recent financial results after the closing bell on Wednesday.
Published:
Catabasis Pharmaceuticalswas absolutely devastated on Tuesday after the company announced top-line results from its late-stage study in muscular dystrophy.
Published:
The October 15 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Published:
BioSig Technologies was absolutely crushed on Monday after the company announced that it would be halting its midstage coronavirus study.
Published:
Clinical-stage biopharmaceutical company Atea Pharma intends to price 11 million shares for and intial public offering valued up to more than $303 million.
Published:
BlondVax Pharma was absolutely crushed on Friday after the company reported late-stage results from its flu vaccine study. Needless to say, results obviously didn’t live up to expectations.
Published:
Gilead Sciences is the first company to cross the finish line for regulatory approval in the fight against the coronavirus.
Published:
Biogen reported better than expected third-quarter financial results with disappointing guidance before the markets opened on Wednesday.
Published:
Aptinyx shares soared on Tuesday after the company provided an update from its midstage study in post-traumatic stress disorder.
Published: